The Psychedelics as Medicine Report: Third Edition
The Psychedelics as Medicine Report: Third Edition provides unparalleled consumer insights and market intelligence from experts and industry leaders, helping investors cut through the noise and identify real opportunities.
The Psychedelics as Medicine Report: Third Edition examines
Proprietary insights from consumers and healthcare providers
Deep dives into the most transformative compounds and companies
Key regulations, transformative trends and commercial opportunities
Table of Contents
Introduction
Definition and Scope
Executive Summary
Key Trends
Market Value
Legislation and Regulation
Consumer Attitudes
Healthcare Providers’ Attitudes
Spotlight on Health
Psychedelics - Timeline of Key Developments
Countries to Watch
Psychedelic Profiles
Key Psychedelics of Note
Psychedelics As Medicines - Potential Therapies
Psychedelics and Technology
Psychedelics per Country
Psychedelics and the Law
Patents and Intellectual Property
Therapists and Doctors
Psychedelic Research
Glossary
Key Trends
Research is at a tipping point
Psychedelics poised to treat many disorders
Therapy will be the name of the game
Legislation and regulation moving in the right direction
Patients and doctors are ready for change
Market Value
Approval landscape
Projected growth of medical psychedelics market
The cost of illness
Economic health model
Mental health during the COVID-19 pandemic
Consumer Attitudes
Consumer’s take on psychedelics as medicine
The education opportunity
Psychedelics of choice
Influence of prior drug use on openness to psychedelic-assisted therapies
Healthcare Provider Attitudes
State of mental health: Healthcare workers
Psychedelic expertise of healthcare workers
Healthcare workers' familiarity with psychedelic-assisted therapy
Therapy: The benefits and challenges
Healthcare workers’ attitudes towards the medical benefits of psychedelics
Influence of psychedelic use on practitioner views
Spotlight on Health
Psychedelics coming out the closet
Novel ways of treating persistant problems
Total number of clinical trials
Key conditions
Percentage of mental health and substance use disorders
Facts about mental health conditions
Psychedelic history and future
Why Psychedelics are different
Key Psychedelic Deep Dives
Psilocybin
LSD
MDMA
Ketamine
Ibogaine
Ayahuasca
Other Psychedelics of Note
Salvia Divinorum
Mescaline
DMT
5-MeO-DMT
Kratom
2C-X
Nitrous Oxide
Psychedelics per Country
Australia
Brazil
Canada
China
Denmark
Germany
Ireland
Netherlands
Spain
Switzerland
United Kingdom
United States
Expert Contributors
Florian Brand – Co-founder and CEO, atai Life Sciences
George Goldsmith – Co-founder and CEO, COMPASS Pathways
Cosmo Feilding Mellen – CEO, Beckley Psytech
Dr Roger McIntyre – CEO, Braxia Scientific
Dr Reid Robison – Chief Medical Officer and Director, Novamind
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Subscribe to the Psychedelics Newsletter
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.